NCT01384734 - HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections | Biotech Hunter

Enrollment

254

Participants

Timeline

Start Date

July 26, 2011

Primary Completion Date

February 18, 2013

Study Completion Date

May 12, 2017

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

BMS-663068 400 mg

Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

DRUG

BMS-663068 800 mg

Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

DRUG

BMS-663068 600 mg

Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

DRUG

BMS-663068 1200 mg

Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

DRUG

Raltegravir 400 mg

Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

DRUG

Tenofovir 300 mg

Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

DRUG

Ritonavir 100 mg

Tablets, Oral, 100 mg, Once daily, 96 weeks

DRUG

Atazanavir 300 mg

Capsules, Oral, 300 mg, Once daily, 96 weeks

Trial Locations (54)

1

GSK Investigational Site, Lima

4

GSK Investigational Site, Lima

13

GSK Investigational Site, Lima

32

GSK Investigational Site, Lima

2000

GSK Investigational Site, Rosario

2010

GSK Investigational Site, Johannesburg

3000

GSK Investigational Site, Dundee

3100

GSK Investigational Site, Mexico City

4001

GSK Investigational Site, Durban

7925

GSK Investigational Site, Observatory, Cape Town

10008

GSK Investigational Site, New York

12157

GSK Investigational Site, Berlin

14000

GSK Investigational Site, DF

14004

GSK Investigational Site, Córdoba

19104

GSK Investigational Site, Philadelphia

20009

GSK Investigational Site, Washington D.C.

20099

GSK Investigational Site, Hamburg

20230

GSK Investigational Site, Aguascalientes

27710

GSK Investigational Site, Durham

28046

GSK Investigational Site, Madrid

30312

GSK Investigational Site, Atlanta

32803

GSK Investigational Site, Orlando

33134

GSK Investigational Site, Coral Gables

44280

GSK Investigational Site, Guadalajara

45170

GSK Investigational Site, Zapopan

53127

GSK Investigational Site, Bonn

75246

GSK Investigational Site, Dallas

75605

GSK Investigational Site, Longview

78240

GSK Investigational Site, San Luis Potosí City

78705

GSK Investigational Site, Austin

80336

GSK Investigational Site, München

94102

GSK Investigational Site, San Francisco

94115

GSK Investigational Site, San Francisco

190103

GSK Investigational Site, Saint Petersburg

191167

GSK Investigational Site, Saint Petersburg

196645

GSK Investigational Site, Saint Petersburg

214006

GSK Investigational Site, Smolensk

700116

GSK Investigational Site, Iași

900709

GSK Investigational Site, Constanța

45267-0405

GSK Investigational Site, Cincinnati

C1202ABB

GSK Investigational Site, Ciudad de Buenos Aires

C1141ACG

GSK Investigational Site, Buenos Aires

C1426EGR

GSK Investigational Site, Buenos Aires

X5000JJS

GSK Investigational Site, Córdoba

S2000CXP

GSK Investigational Site, Rosario

Unknown

GSK Investigational Site, Bogotá

GSK Investigational Site, Craiova

03720

GSK Investigational Site, Distrito Federal

Iqui 01

GSK Investigational Site, Iquitos

Lima 11

GSK Investigational Site, Lima

Lima 31

GSK Investigational Site, Lima

021105

GSK Investigational Site, Bucharest

08916

GSK Investigational Site, Badalona

08036

GSK Investigational Site, Barcelona